Mrs Nikki Reyne
Grant-Funded Researcher (A)
School of Medicine
College of Health
Dr Nikki Reyne is the Preclincal Lead in the Respiratory X-ray Imaging Laboratory and Cystic Fibrosis Airway Research Group. Her research speacialises in pre-clinical models of respiratrory diseases, lung function assessment, and advance respiratory imgaing.
Current research focuses on:
Developing and characterising preclinical models of CF and respiratory infection.
Advancing X-ray Velocimetry (XV) as a novel tool for assessing regional lung ventilation and function.
Investigating how disease progression, infection, and therapies alter lung mechanics and ventilation.
Identifying sensitive imaging biomarkers that can detect early lung disease and treatment responses.
Translating preclinical imaging discoveries toward clinical applications in CF and other respiratory diseases.
Improving understanding of lung function changes across the lifespan in chronic respiratory disease models.
I am a postdoctoral researcher working within the Adelaide Cystic Fibrosis Airway Research Group and the Respiratory X-ray Imaging Laboratory, based at the Women’s and Children’s Hospital in South Australia. My research focuses on improving the understanding, detection, and treatment of respiratory disease through the use of advanced preclinical models, functional lung imaging, and translational therapeutic approaches.
While my primary research area is cystic fibrosis (CF), my work extends broadly across respiratory disease, including muco-obstructive lung disease, chronic bacterial infections, airway obstruction, and other conditions associated with impaired ventilation and lung function. I am particularly interested in how early functional changes within the lung contribute to disease progression, and how emerging technologies can identify these changes before irreversible damage occurs.
My research journey began in 2019 when I undertook an Honours project investigating lentiviral gene therapy in a CF rat model. This work resulted in the first demonstration of in vivo CFTR correction in the nasal airway epithelium, highlighting the potential of genetic therapies to address the underlying cause of CF disease.
My PhD work focused on using X-ray Velocimetry (XV)—a novel imaging modality that captures lung function in real-time—to study respiratory disease in animal models. I have applied XV to assess lung function in CF rats, β-ENaC transgenic mice, and preclinical models of obstructive lung disease. My research has demonstrated regional ventilation differences in these models, contributing to our understanding of disease progression and treatment efficacy.
I also have an interest in bacterial lung infections, particularly Pseudomonas aeruginosa, which remains a significant challenge in CF care. I have developed and characterised a chronic Pseudomonas lung infection model in CF rats to better replicate human disease and assess therapeutic strategies.
In addition to my research responsibilities, I manage the breeding and maintenance of the only two CF rat models in the Southern Hemisphere, which are a vital resource for translational research in Australia.
Research Goals
My long-term research goal is to improve the early detection, monitoring, and treatment of respiratory disease in both paediatric and adult populations. By integrating advanced imaging technologies, functional lung assessments, and therapeutic development, I aim to better understand disease mechanisms, identify early markers of lung dysfunction, and contribute to the development of more effective and personalised respiratory treatments.
| Date | Position | Institution name |
|---|---|---|
| 2025 - ongoing | Post-doctoral Researcher | Adelaide University |
| Date | Institution name | Country | Title |
|---|---|---|---|
| 2024 | University of Adelaide | Australia | PhD |
| The University of Adelaide | Australia | Bachelor of Science - Animal Science | |
| The University of Adelaide | Australia | Bachelor of Science (Honours) |
2025 M. Donnelley, D. Parsons, A. Fouras, A. Tai, N. Eikelis, D. Dharmaprani, R. Smith, N. Reyne, J. Louise. "Improving pediatric respiratory outcomes using x-ray velocimetry functional imaging." $1.9 m
2025 A. McCarron, N. Rout-Pitt, N. Reyne, M. Donnelley. "Delivery: the final barrier to overcome for effective CF airway gene therapy." $80,000
2024 N. Reyne, R, Smith, M. Donnelley and D. Parsons. Robinson Research Institute Step Funding. “X-ray velocimetry lung function imaging in the β-ENaC mouse model of cystic fibrosis.” $14,979.
2024 N. Rout-Pitt, A. McCarron, N. Reyne, D. Parsons. M. Donnelley. Cystic Fibrosis Foundation, "Unravelling the Role of Epithelial-Mesenchymal Transition (EMT) in Cystic Fibrosis Lung Disease: Insights, Challenges, and Therapeutic Prospects", $175,000.
2023 E. Schneider-Futschik, J. Bourke, D. Parsons, H. Chinnery. J. Taylor-Cousar, P. Middleton, A. McCarron and N. Reyne. Cystic Fibrosis Foundation “Delaying the onset of cystic fibrosis pathologies” $282,000
2023 A. McCarron, N. Reyne, P. Cmielewski, M. Donnelley, D. Parsons. Channel 7 Children’s Research Foundation. “Does the presence of lung infection impact the efficacy of cystic fibrosis airway gene therapy?” $40,060.
| Date | Role | Committee | Institution | Country |
|---|---|---|---|---|
| 2026 - ongoing | Convener | Small Interest Group - Cystic Fibrosis TSANZ | TSANZ | Australia |
| 2025 - ongoing | Member | Cystic Fibrosis Conference | CFA | Australia |